

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Top Eminent Healthcare Group Limited **(卓著健康集團有限公司)***

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6877)

INSIDE INFORMATION – PROFIT WARNING

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Top Eminent Healthcare Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 and other information currently available to the Board, compared to the audited results for the year ended 31 December 2024, the Group is expected to record a consolidated net loss attributable to the Shareholders of approximately HK\$7.1 million for the year ended 31 December 2025, as compared to a consolidated net profit attributable to the Shareholders of approximately HK\$11.3 million for the year ended 31 December 2024.

During the year ended 31 December 2025, the Group continued to expand its healthcare business and achieved growth in its business-to-consumer (“**B2C**”) operations. Notwithstanding this, the Group’s overall profitability was adversely affected by a substantial increase in administrative and operating expenses associated with the expansion of its B2C sales channels and digital marketing activities. The Group also incurred higher professional and legal fees relating to specific corporate transactions and ongoing litigation matters during the year. Furthermore, the Group is expected to record other income of approximately HK\$4.6 million for the year ended 31 December 2025, representing a decrease of approximately 71% from the other income of approximately HK\$16.3 million for the year ended 31 December 2024, due to the lower level of foreign exchange gains and interest-related income. These factors collectively contributed to the expected loss for the year ended 31 December 2025.

Looking forward, the Board remains confident about the Group’s recovery and long-term development prospects. The Group will continue to leverage its strategic partnerships and strengthen the momentum of its B2C development, while enhancing the effectiveness of its digital marketing activities and improving overall customer acquisition efficiency. At the same time, the Group will refine its product mix, broaden new product and channel opportunities, reinforce cost discipline, streamline fulfilment and supply chain operations, strengthen operational control, and advance strategic cooperation and new product development. As these initiatives progress and non-recurring costs normalise, the Board expects a gradual improvement in the Group’s financial performance over time.

Forward-looking statements are subject to uncertainties and actual results may differ materially from current expectations.

CAUTION TO SHAREHOLDERS AND POTENTIAL INVESTORS

The Board emphasises that the information contained in this announcement is based solely on the preliminary assessment of the Group's latest unaudited management accounts for the year ended 31 December 2025 and other information currently available to the Board, which have not been audited by the Company's auditors nor reviewed by the audit committee of the Company, and may be subject to adjustments. The consolidated annual results of the Group for the year ended 31 December 2025 are expected to be announced by the Company before the end of March 2026. Shareholders and potential investors are advised to read the annual results announcement of the Company when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company and to seek professional advice when in doubt.

By Order of the Board
Top Eminent Healthcare Group Limited
Ji Guangfei
Chairman

Hong Kong, 4 February 2026

As at the date of this announcement, the Board comprises three Executive Directors, namely Mr. Ji Guangfei (Chairman and Chief Executive Officer), Ms. Li Jiang (Deputy Chairman) and Mr. Zhang Huanping; three Non-Executive Directors, namely Mr. Li Jiong, Mr. Yuan Feng and Mr. Chung Cheuk Fan Marco; and three Independent Non-Executive Directors, namely Mr. Zhou Jiannan (Lead INED), Ms. Hu Zhaoxia and Mr. Lyu Aiping.

* *For identification purpose only*